Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study-Reference-Cited by-同舟云学术

Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

Published:2015-06-22 Issue:8 Volume:12 Page:1239-1250
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Bayas Antonios,Ouallet Jean Christophe,Kallmann Boris,Hupperts Raymond,Fulda Ulrich,Marhardt Kurt

Publisher

Informa Healthcare

Subject

Pharmaceutical Science

Link

http://www.tandfonline.com/doi/pdf/10.1517/17425247.2015.1057567

Reference43 articles.

1. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

2. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis

3. Factors that influence adherence with disease-modifying therapy in MS

4. Narrative Review of the Literature on Adherence to Disease-Modifying Therapies Among Patients with Multiple Sclerosis

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program;Neurology and Therapy;2024-03-26

2. Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives;Neurology and Therapy;2024-01-11

3. Adherence to subcutaneous interferon beta-1a treatment among patients with relapsing multiple sclerosis: the MAIN-MS study;Frontiers in Neurology;2023-11-28

4. The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review;Advances in Therapy;2023-09-21

5. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11